NASDAQ:IGMS IGM Biosciences (IGMS) Stock Price, News & Analysis $6.42 +0.14 (+2.23%) (As of 11:55 AM ET) Add Compare Share Share Today's Range$6.42▼$6.7550-Day Range$6.28▼$11.4752-Week Range$3.81▼$17.70Volume83,591 shsAverage Volume305,034 shsMarket Capitalization$378.91 millionP/E RatioN/ADividend YieldN/APrice Target$17.89 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get IGM Biosciences alerts: Email Address IGM Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside176.1% Upside$17.89 Price TargetShort InterestBearish24.71% of Float Sold ShortDividend StrengthN/ASustainability-1.08Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$47,216 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.31) to ($3.18) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.04 out of 5 starsMedical Sector325th out of 879 stocksPharmaceutical Preparations Industry148th out of 417 stocks 3.3 Analyst's Opinion Consensus RatingIGM Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageIGM Biosciences has only been the subject of 2 research reports in the past 90 days.Read more about IGM Biosciences' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted24.71% of the float of IGM Biosciences has been sold short.Short Interest Ratio / Days to CoverIGM Biosciences has a short interest ratio ("days to cover") of 16.1, which indicates bearish sentiment.Change versus previous monthShort interest in IGM Biosciences has recently increased by 0.78%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldIGM Biosciences does not currently pay a dividend.Dividend GrowthIGM Biosciences does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIGM Biosciences has received a 71.95% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Clinical research services for infectious diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for IGM Biosciences is -1.08. Previous Next 0.6 News and Social Media Coverage Search InterestOnly 1 people have searched for IGMS on MarketBeat in the last 30 days. This is a decrease of -90% compared to the previous 30 days.MarketBeat Follows2 people have added IGM Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IGM Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $47,216.00 in company stock.Percentage Held by Insiders57.00% of the stock of IGM Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.79% of the stock of IGM Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about IGM Biosciences' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for IGM Biosciences are expected to decrease in the coming year, from ($2.31) to ($3.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IGM Biosciences is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IGM Biosciences is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIGM Biosciences has a P/B Ratio of 1.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about IGM Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About IGM Biosciences Stock (NASDAQ:IGMS)IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.Read More IGMS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IGMS Stock News HeadlinesJune 20, 2024 | insidertrades.comFred Schwarzer Sells 4,164 Shares of IGM Biosciences, Inc. (NASDAQ:IGMS) StockJune 19, 2024 | insidertrades.comIGM Biosciences, Inc. (NASDAQ:IGMS) CFO Misbah Tahir Sells 1,570 SharesJuly 8, 2024 | Theo Trade (Ad)Replace Lost Dividend Income with This…Introducing Ultima Trades, a unique strategy designed by Don Kaufman. Ultima Trades capitalize on market inflection points to deliver substantial returns, providing a powerful alternative to traditional dividends. Imagine securing gains like 21%, 30%, or even 305% in just hours or days, ensuring a reliable source of income.May 29, 2024 | globenewswire.comIGM Biosciences to Present at the Jefferies Healthcare ConferenceMay 24, 2024 | markets.businessinsider.comMaintaining Hold on IGM Biosciences: Assessing Acquisition Impact and Awaiting Clinical DataMay 24, 2024 | markets.businessinsider.comIn-Depth Examination Of 6 Analyst Recommendations For IGM BiosciencesMay 23, 2024 | msn.comCureVac, Oragenics, IGM Biosciences among healthcare moversMay 22, 2024 | uk.investing.comIGM Biosciences stock surges as Biogen's deal for HI-Bio is seen as a positiveJuly 8, 2024 | Theo Trade (Ad)Replace Lost Dividend Income with This…Introducing Ultima Trades, a unique strategy designed by Don Kaufman. Ultima Trades capitalize on market inflection points to deliver substantial returns, providing a powerful alternative to traditional dividends. Imagine securing gains like 21%, 30%, or even 305% in just hours or days, ensuring a reliable source of income.May 22, 2024 | msn.comIGM Biosciences up 40% following Biogen HI-Bio buyMay 21, 2024 | investing.comIGM Biosciences Inc (IGMS)May 12, 2024 | seekingalpha.comIGM Biosciences: Unlikely To Move The Needle Again In 2024May 10, 2024 | finance.yahoo.comIGM Biosciences Inc (IGMS) Q1 2024 Earnings: Aligns with EPS Projections Amidst Clinical ...May 9, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), IGM Biosciences (IGMS) and Elanco Animal Health (ELAN)May 9, 2024 | markets.businessinsider.comWedbush Keeps Their Buy Rating on IGM Biosciences (IGMS)May 9, 2024 | investorplace.comIGMS Stock Earnings: IGM Biosciences Meets EPS, Misses Revenue for Q1 2024May 8, 2024 | globenewswire.comIGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate UpdateMay 7, 2024 | globenewswire.comIGM Biosciences to Present at the 2024 RBCCM Global Healthcare ConferenceSee More Headlines Receive IGMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IGM Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/08/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IGMS CUSIPN/A CIK1496323 Webigmbio.com Phone650-965-7873FaxN/AEmployees224Year Founded2010Price Target and Rating Average Stock Price Target$17.89 High Stock Price Target$25.00 Low Stock Price Target$8.00 Potential Upside/Downside+184.9%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($4.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-246,420,000.00 Net Margins-11,255.25% Pretax Margin-11,227.17% Return on Equity-108.07% Return on Assets-54.01% Debt Debt-to-Equity RatioN/A Current Ratio7.98 Quick Ratio7.98 Sales & Book Value Annual Sales$2.13 million Price / Sales174.01 Cash FlowN/A Price / Cash FlowN/A Book Value$3.46 per share Price / Book1.82Miscellaneous Outstanding Shares59,020,000Free Float25,380,000Market Cap$370.65 million OptionableOptionable Beta0.20 Social Links These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Fred M. Schwarzer J.D. (Age 71)CEO, President & Director Comp: $977.66kDr. Bruce A. Keyt Ph.D. (Age 70)Chief Scientific Officer Comp: $692.95kDr. Chris H. Takimoto FACP (Age 65)M.D., Ph.D., Chief Medical Officer Comp: $684.95kMr. Misbah Tahir (Age 48)Chief Financial Officer Comp: $957.6kMr. TS HarigopalSenior Vice President of Group OperationsMr. Steven Weber (Age 48)Senior VP, Corporate Controller & Principal Accounting Officer Mr. Paul C. GraffagninoSenior Vice President of Legal AffairsMs. Suzette Tauber (Age 60)Chief Human Resources Officer Dr. Angus M. Sinclair Ph.D.Senior Vice President of Immuno-OncologyDr. Lisa L. Decker Ph.D. (Age 54)Chief Business Officer Comp: $528.18kMore ExecutivesKey CompetitorsCryoportNASDAQ:CYRXZentalis PharmaceuticalsNASDAQ:ZNTLSchrödingerNASDAQ:SDGRDynavax TechnologiesNASDAQ:DVAXSupernus PharmaceuticalsNASDAQ:SUPNView All CompetitorsInsiders & InstitutionsFred SchwarzerSold 4,164 sharesTotal: $31,563.12 ($7.58/share)Misbah TahirSold 1,570 sharesTotal: $11,900.60 ($7.58/share)Steven WeberSold 495 sharesTotal: $3,752.10 ($7.58/share)Artal Group S.A.Sold 20,000 shares on 5/17/2024Ownership: 5.240%Redmile Group LLCBought 100,936 shares on 5/16/2024Ownership: 5.226%View All Insider TransactionsView All Institutional Transactions IGMS Stock Analysis - Frequently Asked Questions How have IGMS shares performed this year? IGM Biosciences' stock was trading at $8.31 at the beginning of 2024. Since then, IGMS shares have decreased by 22.0% and is now trading at $6.48. View the best growth stocks for 2024 here. How were IGM Biosciences' earnings last quarter? IGM Biosciences, Inc. (NASDAQ:IGMS) posted its quarterly earnings results on Wednesday, May, 8th. The company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.01. The business had revenue of $0.50 million for the quarter, compared to the consensus estimate of $0.71 million. IGM Biosciences had a negative net margin of 11,255.25% and a negative trailing twelve-month return on equity of 108.07%. When did IGM Biosciences IPO? IGM Biosciences (IGMS) raised $125 million in an IPO on Wednesday, September 18th 2019. The company issued 7,800,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, Stifel and Guggenheim Securities served as the underwriters for the IPO. How do I buy shares of IGM Biosciences? Shares of IGMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of IGM Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that IGM Biosciences investors own include Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), ImmunoGen (IMGN), Plug Power (PLUG), Atreca (BCEL) and Carnival Co. & (CCL). This page (NASDAQ:IGMS) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredNYSE biotech company's drug could be as revolutionary as penicillin!NV-387 could be a single drug to treat all of the "tripledemic" viruses and more! See how NV-387 could be h...Financial Markets Daily | Sponsored50-year Wall Street Legend: “Prepare for a cash avalanche”The Dow crossed 40,000 for the first time in history… The S&P has hit over 30 all-time highs since the star...Chaikin Analytics | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IGM Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IGM Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
